IFNB1 and myeloid sarcoma: It is also noteworthy that high doses of type-I IFN treatment may generate autoantibodies, as anti-IFN-β antibodies did appear in a portion of MS patients (3-45%), especially in patients receiving subcutaneous formulation (59).